Abstract
Daprodustat, Oral daprodustat, chronic kidney disease, anemia
ANEMIA
Daprodustat is an oral small molecule hypoxia‐inducible factor (HIF) prolyl hydroxylase inhibitor (PHI) approved in Japan and the United States for the treatment of anemia associated with chronic kidney disease. This phase 1, nonrandomized, 2‐period, crossover study in 6 healthy men characterized and quantified the metabolites generated after a microtracer IV infusion of 50 μg (125 nCi) [Oral daprodustat undergoes oxidative metabolism exclusively and is eliminated via hepatobiliary and urinary excretion.
